Glycocalyx-Rebuilding Therapy for Refractory Shock: Current Evidence and Clinical Implications

Abstract

Refractory shock represents a grave and often fatal complication in critically ill patients, characterized by profound circulatory failure unresponsive to conventional vasopressor support. Recent advances in understanding the endothelial glycocalyx an intricate carbohydrate-rich layer lining the vascular endothelium have illuminated its pivotal role in vascular integrity and inflammation. Glycocalyx disruption is increasingly recognized as a key driver of microvascular dysfunction and organ failure in shock states. This review synthesizes current evidence on the pathophysiology of glycocalyx injury in refractory shock, evaluates the rationale for glycocalyx-rebuilding therapies, and discusses emerging clinical strategies aimed at restoring endothelial function and improving outcomes.

Introduction

Refractory shock, defined as persistent hypotension and tissue hypoperfusion despite aggressive fluid resuscitation and high-dose vasopressors, remains a major challenge in intensive care medicine. Mortality rates exceed 50% in this population, underscoring the need for innovative therapeutic approaches. Recent research has shifted focus towards the vascular endothelium, particularly the glycocalyx, as both a marker and mediator of shock-related pathology. Glycocalyx-preserving and -rebuilding interventions are now under active investigation, promising new avenues for targeted management of refractory shock.

Epidemiology / Disease Burden

Refractory shock can occur in the context of septic, cardiogenic, or hemorrhagic shock and affects a substantial subset of patients admitted to intensive care units (ICUs) worldwide. Epidemiological data indicate that up to 10–20% of patients with septic shock progress to a refractory state, with associated mortality rates of 50–80%. The burden is particularly high in elderly populations and those with multiple comorbidities. Healthcare resource utilization is significant, with prolonged ICU stays, multi-organ support requirements, and considerable economic impact.

Pathophysiology

The endothelial glycocalyx is a dynamic, gel-like structure composed of proteoglycans, glycosaminoglycans (GAGs), and glycoproteins, serving as a barrier to vascular permeability, leukocyte adhesion, and coagulation activation. In shock states, systemic inflammation, oxidative stress, and enzymatic degradation lead to shedding of the glycocalyx, exposing the endothelium to injurious stimuli. Loss of glycocalyx integrity contributes to capillary leak, tissue edema, impaired microcirculatory flow, and ultimately, organ dysfunction. Biomarkers such as syndecan-1 and heparan sulfate fragments have emerged as indicators of glycocalyx degradation and correlate with disease severity and outcomes.

Risk Factors

Risk factors for glycocalyx injury and refractory shock include underlying sepsis, severe trauma, major surgery, pre-existing endothelial dysfunction (e.g., diabetes, atherosclerosis), and exposure to hypervolemic crystalloid resuscitation. Genetic predisposition, advanced age, and chronic inflammatory conditions further increase susceptibility. Iatrogenic factors such as excessive mechanical ventilation pressures and inappropriate fluid management may exacerbate endothelial injury.

Clinical Features

Clinically, refractory shock presents with persistent hypotension, elevated lactate levels, cold extremities, altered mental status, oliguria, and signs of multi-organ dysfunction. Laboratory findings may include abnormal coagulation profiles, elevated inflammatory markers, and evidence of metabolic acidosis. In the context of glycocalyx degradation, increased vascular permeability manifests as interstitial and pulmonary edema, complicating fluid management and oxygenation strategies.

Diagnosis

Diagnosis of refractory shock is primarily clinical, based on hemodynamic parameters and failure to respond to conventional therapies. Assessment of glycocalyx integrity is currently limited to research settings, utilizing biomarkers such as plasma syndecan-1, hyaluronan, and heparan sulfate. Novel imaging modalities including sublingual videomicroscopy allow in vivo visualization of microvascular flow and may indirectly reflect glycocalyx status. However, these techniques are not yet widely available in routine clinical practice.

Treatment & Management

Standard management of refractory shock includes prompt identification and treatment of the underlying cause, optimization of preload and afterload, and escalation of vasopressor and inotropic support. Adjunctive therapies such as corticosteroids, vasopressin, and extracorporeal support may be considered in select cases. Increasingly, attention is being paid to endothelial protection, with avoidance of excessive fluid resuscitation and implementation of lung-protective ventilation strategies. Supportive care remains the cornerstone of management pending further advances in targeted therapies.

Recent Advances / Emerging Therapies

Glycocalyx-rebuilding therapies represent a promising frontier in refractory shock management. Agents such as hydrocortisone, albumin, antithrombin, and recombinant human soluble thrombomodulin have demonstrated glycocalyx-preserving effects in preclinical and early clinical studies. Synthetic GAGs, sulodexide, and supplementation with vitamin C, thiamine, and hydrocortisone (the "metabolic resuscitation" approach) are under active investigation. Early results suggest these interventions may attenuate endothelial injury, reduce capillary leak, and improve organ function. However, large-scale randomized controlled trials are needed to establish efficacy and safety.

Guideline Recommendations

Current international guidelines, such as those from the Surviving Sepsis Campaign, emphasize early recognition, source control, and individualized hemodynamic optimization in shock management. While explicit recommendations for glycocalyx-rebuilding therapies are not yet included, there is growing recognition of the importance of endothelial protection. Ongoing clinical trials will likely inform future guideline updates, with the potential for integration of glycocalyx-targeted strategies in the management of refractory shock.

Conclusion

The endothelial glycocalyx has emerged as a critical determinant of vascular homeostasis and a novel therapeutic target in refractory shock. Disruption of this structure underlies much of the microvascular dysfunction seen in critically ill patients, contributing to adverse outcomes. Early-phase clinical data on glycocalyx-rebuilding therapies are encouraging, suggesting potential benefits in preserving vascular integrity and improving patient survival. As research advances, integration of these therapies into clinical practice may redefine the standard of care for refractory shock, offering renewed hope for this challenging and life-threatening condition.